We are live on ! Find out more
ASMB icon

Assembly Biosciences

98 hedge funds and large institutions have $703M invested in Assembly Biosciences in 2017 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 37 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

236% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 11

95% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 19

63% more capital invested

Capital invested by funds: $432M → $703M (+$271M)

36% more funds holding

Funds holding: 7298 (+26)

12% more call options, than puts

Call options by funds: $5.62M | Put options by funds: $5.03M

0.56% more ownership

Funds ownership: 5.94%6.5% (+0.56%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
98
Holders Change
+26
Holders Change %
+36.11%
% of All Funds
2.22%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
37
Increased
37
Reduced
19
Closed
11
Calls
$5.62M
Puts
$5.03M
Net Calls
+$589K
Net Calls Change
+$2.45M

ASMB Hedge Fund Activity: Q4 2017 in Review

98 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2017, worth a combined $703M — up 63% from $432M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new ASMB positions and 11 closed out — a net gain of 26 holders — while 37 added to existing stakes and 19 trimmed.

The largest buyer was OrbiMed, adding an estimated $17M. The largest seller was Valeo Financial Advisors, exiting entirely with an estimated $4.96M sold.

  • 98 institutional investors held Assembly Biosciences (ASMB) as of Q4 2017, up from 72 in Q3 2017.
  • Funds reported $703M of Assembly Biosciences stock for Q4 2017, up 63% quarter-over-quarter.
  • 37 funds opened new Assembly Biosciences positions in Q4 2017 and 11 closed out, a net change of +26 holders.
  • The largest Assembly Biosciences buyer in Q4 2017 was OrbiMed, an estimated $17M added.
  • The largest Assembly Biosciences seller in Q4 2017 was Valeo Financial Advisors, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2017.